NADAC acquisition cost data for STELARA 90 MG/ML SYRINGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
| 57894006103 | $24,599.06 | 2022-04-20 | Rx |
Generic: Ustekinumab | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $796.0M | 41,716 | 10,914 | $21,990.76 |
| 2020 | $1.1B | 53,677 | 12,914 | $23,029.77 |
| 2021 | $1.6B | 70,502 | 16,156 | $24,235.22 |
| 2022 | $2.3B | 96,974 | 19,969 | $25,729.26 |
| 2023 | $3.0B | 117,068 | 22,930 | $26,818.03 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.